Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme.
Scientists uncover a new approach for treating aggressive cancer
February 24, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022